Who are BROPIRIMINE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vitamin B4, Uloric, Aloprim, Uriadec.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bropirimine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BROPIRIMINE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BROPIRIMINE (BROPIRIMINE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

phase 2 Xanthine dehydrogenase/oxidase Other Small molecule Live · refreshed every 30 min

Target snapshot

BROPIRIMINE (BROPIRIMINE). BROPIRIMINE works by inhibiting the enzyme xanthine dehydrogenase/oxidase.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BROPIRIMINE TARGET	BROPIRIMINE		phase 2		Xanthine dehydrogenase/oxidase
Vitamin B4	ADENINE		marketed	Calculi Dissolution Agent [EPC]	Phosphatidylinositol 4-kinase, PI4K, Leucine-rich repeat serine/threonine-protein kinase 2, Xanthine dehydrogenase/oxidase	2021-01-01
Uloric	FEBUXOSTAT	Takeda	marketed	Xanthine Oxidase Inhibitor [EPC]	Xanthine dehydrogenase/oxidase	2009-01-01
Aloprim	ALLOPURINOL	Casper Pharma Llc	marketed	Xanthine Oxidase Inhibitor [EPC]	Xanthine dehydrogenase/oxidase	1966-01-01
Uriadec	TOPIROXOSTAT	Senwa Kegaku Kenkyushp	marketed		ATP-binding cassette sub-family G member 2, Xanthine dehydrogenase/oxidase, Xanthine dehydrogenase/oxidase

Recent regulatory actions (last 90 days)

2026-03-13 — Aloprim · FDA · approved · US · Casper Pharma Llc

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BROPIRIMINE — Competitive Intelligence Brief. https://druglandscape.com/ci/bropirimine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing